Moderna (MRNA) announced that David Rubenstein, Co-Founder and Co-Chairman of The Carlyle Group (CG), will join Moderna’s Board of Directors, effective August 5, 2024. Upon Mr. Rubenstein’s appointment, directors Robert Langer and Stephen Berenson will also retire from the Board. Mr. Rubenstein will replace Mr. Berenson on the Audit Committee of the Board. Both Dr. Langer and Mr. Berenson have agreed to continue providing advisory services to the Company on key matters following their Board retirement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna Reshuffles Board, Adds Carlyle Co-Founder
- Down 60% in 3 Years, Will Moderna Stock (NASDAQ:MRNA) Fall Further?
- Moderna, Mitsubishi Tanabe enter joint pact to promote mRNA vaccine in Japan
- Moderna Stock (NASDAQ:MRNA): Next-Gen COVID-19 Vaccine Is More Than a Rehash
- U.S. Government Awards Moderna (NASDAQ:MRNA) $176M to Develop Bird Flu Vaccine